A research team from the BIST centre IRB Barcelona and the biotech company Nostrum Biodiscovery has developed a new type of inhibitor that blocks only some of the functions of the p38 protein. The alternative pathway that they inhibit is involved in the damage to cardiac muscle caused by heart attacks or chemotherapy treatments. The study has been published in the journal Nature Communications.
The p38 protein regulates a wide variety of cellular functions and is related to diseases such as chronic inflammation, immunological disorders, and cancer. To date, it has been difficult to find p38 inhibitors for use in clinical practice because the candidates produce toxic effects that preclude their administration at adequate therapeutic doses.
A multidisciplinary team led by Dr. Ángel R. Nebreda, Dr. María J. Macías, and Dr. Modesto Orozco, all at IRB Barcelona and members of the BIST Community, has developed a new type of p38 inhibitor, which preferentially impairs one of the activation pathways of this protein. In particular, these inhibitors block the self-activation (or autophosphorylation) of p38 but allow it to continue to be activated by other mechanisms.
This selective inhibition allows the p38 protein to perform many of its normal functions, thus potentially reducing the side effects associated with its total inhibition.
Specifically, the pathway blocked by the new compounds is involved in cardiac cell death caused by the lack of blood supply and subsequent restoration that occur after myocardial infarction.
The p38 self-activation pathway may also be involved in the heart damage caused by treatment with some anti-tumour chemotherapeutics.
“The selective inhibition of some of the functions of a protein as important and versatile as p38 is an innovative approach that paves the way for the development of new compounds with therapeutic potential,” says Dr. Nebreda, ICREA researcher and head of the Signalling and Cell Cycle lab at IRB Barcelona.
Computational modelling, biochemical and structural studies
Computational techniques were used to predict protein behaviour—a technology developed by Dr. Orozco‘s group and Nostrum Biodiscovery. Nostrum Biodiscovery is a joint spin-off of the Barcelona Supercomputing Center (BSC-CNS), IRB Barcelona, the Catalan Institution for Research and Advanced Studies (ICREA), and the University of Barcelona (UB); and collaborates with IRB Barcelona to perform a drug-discovery process. Particularly, Nostrum Biodiscovery performed hierarchical virtual screenings and in-silico hit optimisation studies that were key for the identification of compounds able to inhibit p38a autophosphorylation.
For the validation and characterisation of these inhibitors, Dr. Nebreda’s group carried out a wide range of biochemical assays, in which they analysed more than 100 compounds.
In addition, structural biology techniques that were undertaken by the group led by Dr. Macías and in collaboration with Dr. Joan Pous (from the IRB Barcelona-CSIC X-ray platform), have revealed how the inhibitors can attach to the structure of the p38 protein thus shedding light on their mechanism of action.
“The type of compounds that we have discovered is very special. They compete with the ATP molecule to bind to the active centre of p38, but they do not have very high affinity. So as soon as the protein is activated by an external factor, ATP displaces the inhibitor and p38 can exert its normal functions,” explains Dr. Lorena González, first author of the study and member of the BIST Community, who carried out this project as part of her thesis at IRB Barcelona.
The team has started collaborating with Dr. Antonio Rodríguez-Sinovas, a specialist in cardiovascular diseases at the Vall d’Hebron Research Institute (VHIR), to validate the possible therapeutic potential of the inhibitors in models of cardiotoxicity.
This project has been funded by an ERC Proof of Concept grant, the Spanish Ministry of Science and Innovation, ”la Caixa” Foundation, the Catalan Agency for the Management of University and Research Grants, the BBVA Foundation, the European Regional Development Fund, and the European Union’s Horizon 2020 programme.
Characterization of p38α autophosphorylation inhibitors that target the non-canonical activation pathway. Lorena González, Lucía Díaz, Joan Pous, Blazej Baginski, Anna Duran-Corbera, Margherita Scarpa, Isabelle Brun-Heath, Ana Igea, Pau Martin-Malpartida, Lidia Ruiz, Chiara Pallara, Mauricio Esguerra, Francesco Colizzi, Cristina Mayor-Ruiz, Ricardo M. Biondi, Robert Soliva, Maria J. Macias, Modesto Orozco & Angel R. Nebreda. Nature Communications (2023) DOI: 10.1038/s41467-023-39051-x
IRB Barcelona press release